Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 5/2005

01.05.2005 | Head and Neck Oncology

RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas

verfasst von: Ken-ichi Nibu, Naoki Otsuki, Kazunari Nakao, Masashi Sugasawa, Jay L. Rothstein

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

The activation of RET proto-oncogene through chromosomal translocation is reported as being unique to papillary thyroid carcinomas. However, the reported prevalence of RET/PTC activation in papillary carcinoma was variable, and the clinical relevance of RET/PTC rearrangements in papillary carcinomas is still controversial. To investigate the roles of RET rearrangement in the carcinogenesis of papillary thyroid carcinoma, we have studied RET activation and p53 overexpression in various thyroid lesions of the Japanese population by immunohistochemical technique. RET activation and p53 overexpression were studied in 40 papillary carcinomas, 6 poorly differentiated carcinomas, 4 undifferentiated carcinomas, 2 medullary carcinomas, 2 follicular carcinomas and 19 follicular adenomas. RET activation was observed in 12 out of 40 papillary carcinomas, while no immunoreactivity of RET was detected in other lesions. P53 overexpression was observed in only 1 of 40 papillary carcinomas, but in 2 poorly differentiated carcinomas and 4 undifferentiated carcinomas. The prevalence of RET/PTC activation in papillary carcinoma among the Japanese population was higher than in previous reports. Immunohistochemical technique is proved to be a useful tool to detect RFT/PTC activation in thyroid tumors. RET rearrangements are restricted to a well-differentiated papillary carcinoma, suggesting that RET/PTC positive papillary carcinomas do not progress to undifferentiated carcinoma.
Literatur
1.
Zurück zum Zitat Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL (2001) Analysis of ret/PTC gene rearrangements refines the fine-needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 86:2187–2190 Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL (2001) Analysis of ret/PTC gene rearrangements refines the fine-needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 86:2187–2190
2.
Zurück zum Zitat Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM (1995) High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 11:2459–2467PubMed Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM (1995) High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 11:2459–2467PubMed
3.
Zurück zum Zitat Mai KT, Vaccani JP, Thomas J, Odell PF (2001) Immunostaining for ret oncogene proteins in papillary thyroid carcinoma: a correlation of ret immunoreactivity and potential of lymph node metastasis. Thyroid 11:859–863CrossRefPubMed Mai KT, Vaccani JP, Thomas J, Odell PF (2001) Immunostaining for ret oncogene proteins in papillary thyroid carcinoma: a correlation of ret immunoreactivity and potential of lymph node metastasis. Thyroid 11:859–863CrossRefPubMed
4.
Zurück zum Zitat Motomura T, Nikiforov YE, Namba H, Ashizawa K, Nagataki S, Yamashita S, Fagin JA (1998) ret rearrangements in Japanese pediatric and adult papillary thyroid cancers. Thyroid 8:485–489PubMed Motomura T, Nikiforov YE, Namba H, Ashizawa K, Nagataki S, Yamashita S, Fagin JA (1998) ret rearrangements in Japanese pediatric and adult papillary thyroid cancers. Thyroid 8:485–489PubMed
5.
Zurück zum Zitat Nikiforov YE, Nikiforova MN, Gnepp DR, Fagin JA (1996) Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after Chernobyl nuclear. Oncogene 13:687–697PubMed Nikiforov YE, Nikiforova MN, Gnepp DR, Fagin JA (1996) Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after Chernobyl nuclear. Oncogene 13:687–697PubMed
6.
Zurück zum Zitat Powell D, Russell J, Nibu K, Li K, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A, Rothstein JL (1998) The RET/PTC3 oncogene: metastatic solid-type carcinomas in murine thyroids. Cancer Res 58:5523–5528PubMed Powell D, Russell J, Nibu K, Li K, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A, Rothstein JL (1998) The RET/PTC3 oncogene: metastatic solid-type carcinomas in murine thyroids. Cancer Res 58:5523–5528PubMed
7.
Zurück zum Zitat Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A, Tallini G (2002) RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87:370–379 Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A, Tallini G (2002) RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87:370–379
8.
Zurück zum Zitat Takahashi M (1995) Oncogenic activation of the ret portooncogene in thyroid cancer. Crit Rev Oncog 6:35–46PubMed Takahashi M (1995) Oncogenic activation of the ret portooncogene in thyroid cancer. Crit Rev Oncog 6:35–46PubMed
9.
Zurück zum Zitat Takahashi M (2001) The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12:361–373CrossRefPubMed Takahashi M (2001) The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12:361–373CrossRefPubMed
10.
Zurück zum Zitat Tallini G, Asa L (2001) RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8:345–354CrossRefPubMed Tallini G, Asa L (2001) RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8:345–354CrossRefPubMed
11.
Zurück zum Zitat Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidince of progression to poorly differentiated or undifferentiated tumor phenotypes. Clinical Cancer Res 4:287–294 Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidince of progression to poorly differentiated or undifferentiated tumor phenotypes. Clinical Cancer Res 4:287–294
12.
Zurück zum Zitat Wajjwalku W, Nakamura S, Hasegawa Y, Miyazaki K, Satoh Y, Funahashi H, Matsuyama M, Takahashi M (1992) Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res 83:671–675PubMed Wajjwalku W, Nakamura S, Hasegawa Y, Miyazaki K, Satoh Y, Funahashi H, Matsuyama M, Takahashi M (1992) Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res 83:671–675PubMed
13.
Zurück zum Zitat Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, Multhaupt H, Atkins JP, Rosen MR, Keane W, Rothstein JL (1997) Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto’s thyroiditis. Laryngoscope 107:95–100CrossRefPubMed Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, Multhaupt H, Atkins JP, Rosen MR, Keane W, Rothstein JL (1997) Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto’s thyroiditis. Laryngoscope 107:95–100CrossRefPubMed
Metadaten
Titel
RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas
verfasst von
Ken-ichi Nibu
Naoki Otsuki
Kazunari Nakao
Masashi Sugasawa
Jay L. Rothstein
Publikationsdatum
01.05.2005
Verlag
Springer-Verlag
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 5/2005
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-004-0835-8

Weitere Artikel der Ausgabe 5/2005

European Archives of Oto-Rhino-Laryngology 5/2005 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.